Agenus

Agenus Liabilities

The The Liabilities of Agenus (AGEN) as of Nov 13, 2026 is 504.66 M USD. In the previous year, The Liabilities was 532.70 M USD — a change of -5.26% (lower).

Liabilities

504.66 MUSD

YoY

-5.26%

Last updated:

In 2025, Agenus's total liabilities amounted to 504.66 M USD, a -5.26% difference from the 532.70 M USD total liabilities in the previous year.

The Agenus Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
310.95 M USD
Jan 1, 2019
386.67 M USD
Jan 1, 2020
426.01 M USD
Jan 1, 2021
418.05 M USD
Jan 1, 2022
468.46 M USD
Jan 1, 2023
462.30 M USD
Jan 1, 2024
532.70 M USD
Jan 1, 2025
504.66 M USD
The Agenus Liabilities history
YEARLiabilitiesYoY
504.66 MUSD-5.26%
532.70 MUSD+15.23%
462.30 MUSD-1.32%
468.46 MUSD+12.06%
418.05 MUSD-1.87%
426.01 MUSD+10.17%
386.67 MUSD+24.35%
310.95 MUSD+45.15%
214.22 MUSD+9.23%
196.11 MUSD+14.35%
171.50 MUSD+232.95%
51.51 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Agenus Stock analysis

What does Agenus do? Agenus, Inc. develops immuno-oncology therapies focused on engaging the immune system to treat cancer. The company's product portfolio includes antibody discovery platforms like Retrocyte Display, SECANT yeast display, and phage display technologies for human antibody production. Its antibody candidate programs feature checkpoint modulator (CPM) programs, while vaccine programs consist of Prophage, AutoSynVax, and PhosPhoSynVax, supported by the QS-21 Stimulon adjuvant. Agenus targets clinical-stage development for cancer and infectious disease treatments, leveraging its proprietary platforms to advance therapies through its discovery pipeline. The company's revenue streams come from its clinical-stage immuno-oncology programs, with products such as the QS-21 Stimulon adjuvant used in vaccine development. Agenus commercializes its technologies through partnerships and licensing agreements for its antibody platforms and vaccine candidates. Its target segments include pharmaceutical companies seeking advanced immuno-oncology solutions and vaccine developers requiring adjuvant technology. The firm's focus on checkpoint modulators and heat shock protein-based vaccines positions it to serve the oncology and infectious disease markets through its proprietary platforms and programs. Agenus develops therapies using antibody discovery platforms including Retrocyte Display, SECANT yeast display, and phage display. Its vaccine candidates like Prophage, AutoSynVax, and PhosPhoSynVax are supported by the QS-21 Stimulon adjuvant. The company's CPM programs and HSP-based vaccine platforms drive its clinical development pipeline. Agenus targets pharmaceutical firms and vaccine developers as key customers for its immuno-oncology technologies and adjuvant solutions, focusing on cancer and infectious disease applications. Agenus is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Agenus's Liabilities

Agenus's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Agenus's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Agenus's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Agenus's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Agenus’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Agenus stock

The Liabilities of Agenus is 504.66 M USD in 2025.

The Liabilities of Agenus changed from 532.70 M USD to 504.66 M USD, representing a -5.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Agenus since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Agenus historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Agenus

All Key Metrics — Agenus